Literature DB >> 15106092

Acute measles mortality in the United States, 1987-2002.

Jacqueline Gindler1, Sarah Tinker, Lauri Markowitz, William Atkinson, Loring Dales, Mark J Papania.   

Abstract

We used capture-recapture methodology to estimate total deaths and efficiency of reporting for 2 systems. During 1987-1992, there were 165 measles-associated deaths in the multiple-cause mortality database at the National Center for Health Statistics (NCHS) and 184 reported to the measles surveillance system at the National Immunization Program (NIP). We estimated that 259 measles deaths actually occurred; the reporting efficiencies were 64% for the NCHS and 71% for the NIP. Overall the death-to-case ratio was 2.54 and 2.83 deaths/1000 reported cases, using the NCHS and NIP data, respectively. Pneumonia was a complication among 67% of measles-related deaths in the NCHS data and 86% of deaths in the NIP data. Encephalitis was reported in 11% of deaths in both databases. Preexisting conditions related to immune deficiency were reported for 16% of deaths in the NCHS system and 14% in the NIP; the most common was human immunodeficiency virus infection. Overall, 90% of deaths reported to the NIP occurred in persons who had not been vaccinated against measles. During 1993-1999, only 1 acute measles-related death was reported to the NCHS and no deaths were reported to the NIP. This is consistent with the extremely low reported incidence of measles in the United States during these years.

Entities:  

Mesh:

Year:  2004        PMID: 15106092     DOI: 10.1086/378565

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Matrix protein-specific IgA antibody inhibits measles virus replication by intracellular neutralization.

Authors:  Dihan Zhou; Yan Zhang; Qiaoli Li; Yaoqing Chen; Benxia He; Jingyi Yang; Haobo Tu; Lei Lei; Huimin Yan
Journal:  J Virol       Date:  2011-08-24       Impact factor: 5.103

2.  Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age.

Authors:  Hayley A Gans; Linda L Yasukawa; Phillip Sung; Barbara Sullivan; Ross DeHovitz; Susette Audet; Judy Beeler; Ann M Arvin
Journal:  J Infect Dis       Date:  2013-01-08       Impact factor: 5.226

Review 3.  The role of research in viral disease eradication and elimination programs: lessons for malaria eradication.

Authors:  Joel G Breman; Ciro A de Quadros; Walter R Dowdle; William H Foege; Donald A Henderson; T Jacob John; Myron M Levine
Journal:  PLoS Med       Date:  2011-01-25       Impact factor: 11.069

4.  Fatal measles without rash in immunocompetent adult, France.

Authors:  Julien Lupo; Sylvain Bernard; Claire Wintenberger; Monique Baccard; Astrid Vabret; Denise Antona; Jean-François Timsit; Patrice Morand
Journal:  Emerg Infect Dis       Date:  2012-03       Impact factor: 6.883

5.  Inpatient morbidity and mortality of measles in the United States.

Authors:  Raj Chovatiya; Jonathan I Silverberg
Journal:  PLoS One       Date:  2020-04-28       Impact factor: 3.240

6.  Prevalence of measles in vaccinated and non-vaccinated children.

Authors:  Muhammad Asif Zahoor; Muhammad Hidayat Rasool; Muhammad Waseem; Bilal Aslam; Muhammad Kashif Zahoor; Muhammad Saqalein; Zeeshan Nawaz; Rabia Sahar
Journal:  EXCLI J       Date:  2015-04-01       Impact factor: 4.068

7.  Sero-epidemiology and Risk Factor Analysis of Measles Among Children in Pakistan.

Authors:  Muhammad Hidayat Rasool; Ahsan Rafiq; Muhammad Zeeshan Nawaz; Muhammad Shafique; Muhammad Saqalein
Journal:  Pol J Microbiol       Date:  2018-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.